Literature DB >> 7713138

[3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors.

A M Gonzalez1, D R Sibley.   

Abstract

The binding of [3H](+)-7-hydroxy-2-(N,N-di-n-propylamino)tetralin ([3H]7-OH-DPAT) to dopamine D2 and D3 receptors expressed in Chinese hamster ovary (CHO) cells was investigated and compared with [3H]methylspiperone. [3H]7-OH-DPAT labeled the D3 receptor in the CHO cells in a guanine nucleotide-insensitive fashion and exhibited a Kd of about 0.5 nM. In the presence of MgCl2. [3H]7-OH-DPAT was also found to label the D2 receptor in CHO cells with high affinity (3.6 nM). The binding of [3H]7-OH-DPAT to the D2 receptor was sensitive to guanine nucleotides suggesting occupancy of a high affinity G protein-coupled state of the receptor. These results suggest that caution should be exercised when using [3H]7-OH-DPAT to label the dopamine D3 receptor in brain tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7713138     DOI: 10.1016/0014-2999(94)00738-s

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.

Authors:  Jinbin Xu; Babak Hassanzadeh; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2010-06       Impact factor: 2.562

2.  Visualisation of the cortical dopamine D3 receptors in alcoholics and controls with human whole-hemisphere autoradiography.

Authors:  Erkki Tupala; Håkan Hall; Jari Tiihonen
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 3.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

Review 4.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

5.  [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.

Authors:  Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

6.  Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

Authors:  M C Coldwell; I Boyfield; T Brown; J J Hagan; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

7.  Upregulation of (+)-7-hydroxy-N,N-di-n-[3H]propyl-2-aminotetralin binding following intracerebroventricular administration of a nitric oxide generator.

Authors:  D R Wallace; R M Booze
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

Review 8.  Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.

Authors:  T E Koeltzow; M Xu; D C Cooper; X T Hu; S Tonegawa; M E Wolf; F J White
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

9.  Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine.

Authors:  R Depoortere; G Perrault; D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

10.  Neuropharmacological evidence for the role of dopamine in ventral pallidum self-stimulation.

Authors:  G Panagis; C Spyraki
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.